Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi sells off smallpox vaccine business to Emergent BioSolutions

Sanofi sells off smallpox vaccine business to Emergent BioSolutions

11th October 2017

Sanofi has finalised the sale of its ACAM2000 smallpox vaccine business and associated assets to Emergent BioSolutions.

The deal, worth up to $117.5 million (89.08 million pounds), includes an upfront fee of $97.5 million and $20 million in milestone-based payments, contingent upon certain regulatory and manufacturing-related milestones being met.

ACAM2000 is the only smallpox vaccine approved by the US Food and Drug Administration, with this acquisition also seeing Emergent assume responsibility for an existing ten-year contract with the Centers for Disease Control and Prevention for the delivery of ACAM2000 to the US Strategic National Stockpile (SNS).

The deal includes a cGMP live viral manufacturing facility and office and warehouse space in Canton, Massachusetts, as well as a viral fill/finish facility in Rockville, Maryland.

Daniel Abdun-Nabi, president and chief executive officer of Emergent BioSolutions, said: "We look forward to integrating the ACAM2000 business into our operations and working with the US government to ensure an uninterrupted supply of ACAM2000 to the SNS."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.